samedan logo

 
 
spacer
home > ebr > summer 2008 > protein potential
PUBLICATIONS
European Biopharmaceutical Review

Protein Potential

Interferon alpha (IFNα) was one of the first FDA-approved biotherapeutic treatments. Since its approval, it has proved to be a powerful cytokine with potent therapeutic activity but, unfortunately, strong side effects. The overall use of IFNα increased dramatically when it was approved as the treatment of choice for hepatitis C.

However, nearly half of the individuals infected with genotype 1 of the virus still fail to respond to therapy (1). Consequently, several pharmaceutical companies are now trying to turn on the body’s own interferon alpha family of proteins using immunomodulatory molecules in the hope that this will elicit a more complete antiviral response. Both therapeutic approaches are not without risk, due to the side effects associated with IFNα. Additionally, there is a growing amount of published scientific articles suggesting that IFNα may be involved in certain autoimmune diseases, including systemic lupus erythematosus (SLE) (2).

Combined, these observations clearly suggest an increased need to monitor IFNα levels in both normal and diseased individuals along with patients undergoing therapy. How much IFNα produced by the body in response to new immunomodulatory therapies will be functionally equivalent to the current IFNα exogenous treatment regimen? How much ‘basal’ IFNα is beneficial to prevent or limit viral infection and how much is too much, thereby predisposing an individual to autoimmune disorders?


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
Ronald G Jubin PhD is the current Research and Development Director at PBL InterferonSource. Previously, he was a Research Scientist with Schering-Plough from 1992 to 2004 in the antiviral therapy department, working on hepatitis C virus and interferon antiviral mechanisms. Whilst there, he published several papers that helped better define the mechanism of HCV translation. Ronald received his BA in Microbiology from Kean University, his MS degree in Microbiology from Seton Hall University and his PhD in Microbiology and Molecular Genetics from the University of Medicine and Dentistry of New Jersey, US.
spacer
Ronald G Jubin
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

SGS QUAY PHARMA RECEIVES QUEEN’S AWARD FOR INDUSTRY

Leading pharmaceutical contract development and manufacturing organisation (CDMO) SGS Quay Pharma has received its Queen’s Award for Enterprise. The award was presented by the Lord Lieutenant of Clwyd, Henry Fetherstonhaugh, OBE, in a special ceremony at the company’s global headquarters in Deeside Industrial Park, Flintshire.
More info >>

White Papers

Clinical Trials in Russia Orange Paper: Summary of Year 2013

Synergy Research Group

Russia remains a very popular geography for local, regional, and global pharmaceutical companies to conduct clinical trials. Sponsors mention the following reasons for conducting studies in Russia: 1. Fast patient enrollment due to the centralized medical infrastructure. 2. Nearly 100% patient retention 3. GCP trained and certified Investigative Sites generating high quality data 4. Low cost: Average per patient cost is 60% to 70% below US and European prices due to the low cost of Investigators and the high concentration of patients in therapeutically aligned medical centers
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement